ACCURAY WKN: A0MKWM ISIN: US0043971052 Kürzel: XEJ Forum: Aktien Thema: Hauptdiskussion

https://www.prnewswire.com/news-releases/new-data-from-two-clinical-studies-indicate-high-risk-and-recurrent-prostate-cancers-can-be-effectively-treated-in-5-days-using-the-accuray-cyberknife-system-302099017.html

https://www.nasdaq.com/articles/three-reasons-to-retain-accuray-aray-stock-in-your-portfolio

Roth/MKM sets $9 stock target on Accuray, bullish on market expansion https://m.uk.investing.com/news/stock-market-news/rothmkm-sets-9-stock-target-on-accuray-bullish-on-market-expansion-93CH-3335248

Accuray GAAP EPS of -$0.10 misses by $0.05, revenue of $107.2M beats by $0.53M https://seekingalpha.com/news/4060915-accuray-gaap-eps-of-0_10-misses-0_05-revenue-of-107_2m-beats-0_53m • Accuray press release (NASDAQ:ARAY): Q2 GAAP EPS of -$0.10 misses by $0.05. • Revenue of $107.2M (-6.6% Y/Y) beats by $0.53M. • The company is reaffirming guidance for fiscal year 2024 as follows: • Total revenue is expected in the range of $460 million to $470 million, vs. consensus of $463.17M, representing a year-over-year growth range of 3 to 5 percent. • Adjusted EBITDA for fiscal year 2024 is expected in the range of $27 million to $30 million.

https://investors.accuray.com/news-releases/news-release-details/accuray-reports-fiscal-2024-second-quarter-financial-results Accuray Reports Fiscal 2024 Second Quarter Financial Results 19% Order Growth YOY; 8% Service Revenue Expansion; Confirms FY24 Guidance

.

Accuray Reports Fiscal 2024 First Quarter Financial Results https://investors.accuray.com/news-releases/news-release-details/accuray-reports-fiscal-2024-first-quarter-financial-results Company Achieves 8% Revenue Growth, Reiterates FY 2024 Guidance

https://www.massdevice.com/accuray-lays-off-nearly-6-of-global-workforce/

Accuray (ARAY) Positioned for Growth: Buy Rating Supported by Chinese Market Expansion, New Product Launches, and Strong Financial Projections https://markets.businessinsider.com/news/stocks/accuray-aray-positioned-for-growth-buy-rating-supported-by-chinese-market-expansion-new-product-launches-and-strong-financial-projections-1032677267

https://www.benzinga.com/pressreleases/23/10/n35072403/accuray-announces-approval-of-the-tomo-c-radiation-treatment-delivery-system-by-chinas-national-me

Accuray and Limbus AI Unveil Online Adaptive Therapy Solution for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting https://investors.accuray.com/news-releases/news-release-details/accuray-and-limbus-ai-unveil-online-adaptive-therapy-solution ...Cenos is designed to enable medical care teams to quickly and efficiently make adjustments, if necessary, to a treatment plan while the patient is still on the treatment table. ...

.

https://finance.yahoo.com/news/accurays-aray-treatment-options-boosted-133000149.html

👀

Accuray Receives FDA Clearance for VitalHold™ on the Radixact® System; Breast Cancer Treatment Option Will Also Be Available in the EU Market https://www.prnewswire.com/news-releases/accuray-receives-fda-clearance-for-vitalhold-on-the-radixact-system-breast-cancer-treatment-option-will-also-be-available-in-the-eu-market-301895530.html

Accuray GAAP EPS of -$0.03 misses by $0.04, revenue of $118.3M misses by $3.44M https://seekingalpha.com/news/4000416-accuray-gaap-eps-of-0_03-misses-0_04-revenue-of-118_3m-misses-3_44m • Accuray press release (NASDAQ:ARAY): Q4 GAAP EPS of -$0.03 misses by $0.04. • Revenue of $118.3M (+7.5% Y/Y) misses by $3.44M. • The Company is introducing guidance for fiscal year 2024 as follows: • Total revenue is expected in the range of $460 million to $470 million vs $451.05M consensus, representing a year-over-year growth range of 3% to 5%. • Adjusted EBITDA is expected in the range of $27 million to $30 million.